Reuters: Hot Stocks: Biogen prices new MS drug at discount to key competitors

Reuters: Hot Stocks Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Biogen prices new MS drug at discount to key competitors Mar 29th 2013, 17:26 WASHINGTON, March 29 | Fri Mar 29, 2013 1:26pm EDT WASHINGTON, March 29 (Reuters) - Biogen Idec Inc said on Friday it will charge $54,900 a year for its multiple sclerosis drug, Tecfidera, which received U.S. approval on Wednesday. The company has priced the drug at a discount to key competitors such as Novartis AG's MS pill Gilenya, which costs roughly $60,000 a year, in a bid to maximize its market share. "We think this represents solid value to the MS community and demonstrates our commitment to patient access," said Kate Niazi-Sai, a Biogen spokeswoman. The price is somewhat higher than the low $50,000-range expected by fund managers polled by Mark Schoenebaum, an analyst at ISI Group, but largely in line with analysts' expectations. Tecfidera is a pill that is widely expected to become the leading oral treatment for MS, steadily taking market share from older, injectible treatments such as Teva Pharmaceutical Industries' Copaxone, which is currently the market leader. Tecfidera is expected to generate sales of more than $3 billion, according to Thomson Reuters data. (Reporting by Toni Clarke, editing by G Crosse) Link this Share this Digg this Email Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions